Outcomes following natalizumab exposure throughout pregnancy in patients with relapsing multiple sclerosis (RMS) or Crohns disease (P1.362)

Conclusions:This review revealed 24 prospectively reported pregnancies that had been exposed to natalizumab for the duration of the pregnancy. All reported pregnancies resulted in live births, with no reported birth defects. Reported hematological abnormalities resolved in all cases.Study Supported by: BiogenDisclosure: Dr. Friend has received personal compensation for activities with Biogen as an employee. Dr. Friend has hold stock and/or stock options in Biogen. Dr. Haddock has received personal compensation for activities with Biogen Idec as an employee. Dr. Haddock holds stock and/or stock options in Biogen Idec, which sponsored research in which Dr. Haddock was involved as an investigator. Dr. Campagnolo has received personal compensation for activities with Biogen as an employee. Dr. Lee has received personal compensation for activities with Biogen as an employee.

Source: Neurology - April 17, 2017 Category: Neurology Authors: Friend, S., Haddock, B., Campagnolo, D., Lee, L. Tags: Pregnancy and Multiple Sclerosis Source Type: research